# Bruce E. Johnson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bruce-e-johnson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 87,720 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 122 |
| i10-index | 379 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5053521833 |
| ORCID iD | https://orcid.org/0000-0002-5252-3677 |
| Works | 1,083 |

## Researcher papers

Showing 12 of 21.

- [<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy](https://scholariq.org/papers/i-egfr-i-mutations-in-lung-cancer-correlation-with-clinical-response-to/)
- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib](https://scholariq.org/papers/i-egfr-i-mutation-and-resistance-of-non-small-cell-lung-cancer-to-gefitinib/)
- [Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing](https://scholariq.org/papers/mapping-the-hallmarks-of-lung-adenocarcinoma-with-massively-parallel-sequencing/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-untreated-brafv600e/)
- [The BATTLE Trial: Personalizing Therapy for Lung Cancer](https://scholariq.org/papers/the-battle-trial-personalizing-therapy-for-lung-cancer/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)
- [First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations](https://scholariq.org/papers/first-line-gefitinib-in-patients-with-advanced-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.